CME: Management strategies for complications of chronic kidney disease (CKD): Anemia and hyperphosphatemia
ACCREDITATION EXPIRED: March 24, 2022
Activity Description / Statement of Need:
In this online, self-learning activity:
Chronic Kidney Disease (CKD) affects about 15% of the general population in the United States according to data from the CDC’s National Health and Nutrition Examination Survey and causes a number of complications with anemia and hyperphosphatemia common among them. Anemia occurs in about 15% of patients and arises from a result of decreased production of erythropoietin (EPO) which signals bone marrow to produce red blood cells, whereas hyperphosphatemia occurs in the later stages of CKD because the kidney is the primary method by which the body maintains phosphate. This retention of phosphate leads to the development of CKD-Mineral Bone Disorder (CKD-MBD), with the literature suggesting that hyperphosphatemia occurs in a large portion of patients on dialysis based on usage of phosphate binders (PBs).
Anemia and hyperphosphatemia are associated with higher morbidity and mortality in patients in late CKD, especially those undergoing dialysis.
Target Audience:
The following healthcare professionals (HCPs): nephrologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in nephrology; and any other HCPs with an interest in or who clinically encounter patients with CKD.
Commercial Support Disclosure: This activity is supported by an educational grant from Akebia.
Learners may participate in this activity free of charge.
Release Date: March 24, 2020 -- Expiration Date: March 24, 2022
Faculty: Phuong Chi Pham, MD
Agenda
|
Faculty introduction and disclosures |
|
Epidemiology and overview of anemia and hyperphosphatemia in CKD
|
|
Treatment of anemia and hyperphosphatemia in CKD
|
|
Patient case(s)
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe common complications that patients with CKD experience
- Describe management strategies for anemia and hypherphosphatemia of CKD and their impact
- Determine appropriateness of therapies for anemia and hypherphosphatemia of CKD, given a patient case
- Describe effective management strategies for monitoring anemia and hyperphosphatemia in patients with CKD, taking into account dialysis status
Accreditation
ACCME Activity #201471473
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Phuong Chi Pham, M.D., University of California Los Angeles, has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This activity is supported by an educational grant from Akebia.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Renal Cell Carcinoma (RCC): Optimizing Pharmacotherapeutic and Interventional Management Strategies
Updates in alcohol use disorder (AUD) pharmacotherapy and barriers to optimal care